Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In cytology, it is often difficult to make a definite diagnosis of endometrial cancer. In order to devise a new supplementary method, using flow cytometry we analyzed the reactivities of endometrial cells with two monoclonal antibodies (MSN-1 and MSN-3), both of which are strongly reactive to endometrial cancer cells. Employing either or both antibodies in flow cytometry, we investigated the usefulness of this analysis for distinguishing endometrial cancer cells from normal endometrial cells. Results revealed a low positive rate for normal endometrium: 9.2% with MSN-1 and 5.0% with MSN-3. In contrast, for endometrial cancer the positive rate was high: 81.2% with MSN-1 and 43.8% with MSN-3. Combined analysis with both antibodies increased the positive rate for endometrial cancer to 93.7%. These results suggest that analysis by flow cytometry employing MSN-1 and MSN-3 may have a diagnostic value for endometrial cancer. We are also investigating the usefulness of two-color analysis using these antibodies.
 ...
PMID:[Development of a new supplementary diagnostic method for endometrial cancer by flow cytometry employing anti-endometrial cancer antibody, MSN-1 and MSN-3]. 128 Mar 7

The reactivity of a new monoclonal antibody (MAb), MSN-1, raised against a human endometrial cancer cell line (SNG-II), was studied in a variety of endometrial, endocervical, and ovarian carcinomas as well as normal cycling endometrium. Moderate to strong reactivity (2-3+) was seen in six of nine normal secretory endometria (67%), one of 10 normal proliferative endometria (10%), 18 of 18 endometrial adenocarcinomas (100%), 10 of 11 endometrioid ovarian adenocarcinomas (91%), seven of nine clear cell ovarian adenocarcinomas (78%), one of 12 endometrial hyperplasias without atypia (9%), two of four endometrial hyperplasias with atypia (50%), zero of five endometrial serous adenocarcinomas, two of 17 serous ovarian adenocarcinomas (12%), zero of 10 intestinal-type mucinous ovarian adenocarcinomas, and zero of nine metastatic adenocarcinomas in ovary. Endocervical adenocarcinomas showed moderate to strong staining in 75% (six of eight). It is concluded that MSN-1 can be used to confirm endometrioid/clear cell differentiation in ovarian and endometrial tumors, cannot be used to discriminate endocervical from endometrial differentiation, cannot be used to discriminate atypical hyperplasia from carcinoma, and may be useful to distinguish between atypical (premalignant) endometrial hyperplasias and those without atypia.
 ...
PMID:MSN-1 antibody in the evaluation of female genital tract adenocarcinomas. 229 65

To determine a phenotypic difference between normal endometrium and endometrial adenocarcinoma, a new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II), which was established in 1981 from a 43-year-old Japanese woman with stage II uterine endometrial cancer. MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid and seldom reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. By application of MSN-1 to flow cytometry, the possibility of differentiating endometrial normal cells from cancer cells was demonstrated.
 ...
PMID:A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. 238 76

Since cultured cells have the possibility to produce tumor-associated substances in vitro, we generated several monoclonal antibodies using cultured cells as immunogen and applied them to cancer diagnosis. Two monoclonal antibodies (F602-1 and F602-6) were generated against a newly established ovarian mesonephroid cancer cell line (RMG-II), and a double determinants sandwich enzyme-immunoassay system was developed. Their epitopes were proved to exist on the CA125 molecules, but to be different from the one recognized by OC125, and almost the same result of serum assay as CA125 was obtained by this assay. A new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II). MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid, and seldom reacted immunohistochemically with normal endometrium, but reacted with about 90% of endometrial cancer cases. By application of MSN-1 to flow-cytometry, the possibility of differentiating endometrial normal cells from the cancer cells was demonstrated.
 ...
PMID:[Monoclonal antibodies raised against cultured cells and their application in cancer diagnosis]. 273 79

Using human cultured cell lines or lymphocytes, two kinds of murine- and one human-monoclonal antibodies were produced, respectively and their clinical usefulness were investigated, and the possibility of galactosyl-transferase as a new tumor maker was also discussed. (1) A murine monoclonal antibody MSN-1, which was raised against human endometrial cancer cell line and recognized blood type sugar chain Leb, reacted with about 85% of endometrial cancer tissues, indicating that useful clinical information may be obtained by applying MSN-1 to immunohistochemistry and flow cytometry. (2) A new assay system using two murine monoclonal antibodies MA54 and MA61, which were raised against human lung cancer cell line and reacted with mucin sugar residues, revealed 76% positive rate in ovarian cancer patients, especially 82% in mucinous cystadenocarcinoma, indicating the clinical effectiveness as a new tumor maker compensating for the drawbacks of CA-125. (3) Galactosyl-transferase isozyme GT-2 was analyzed by the assay system using a newly produced monoclonal antibody. GT-2 was positive in 74% of ovarian cancers, especially in 89% of meso-nephroid cancer, indicating that GT-2 could be a useful tumor maker in ovarian tumors. (4) Human monoclonal antibody, which recognized "type 1 sugar chain" or iso-paragloboside, reacted about one half of endometrial cancer tissues. The production of human monoclonal antibody may contribute to the cancer imaging and the missile therapy.
 ...
PMID:[On the clinical usefulness of a few sugar antigens and a galactosyl-transferase]. 315 88

An increased rate of expression of Lewis group antigens, particularly Lewisb antigen, was observed in endometrial cancers compared with its expression in normal endometria. In order to elucidate the expression mechanism of Lewisb antigen in endometrial cancer, the level of fucosyltransferase (FT) was examined. The levels of alpha 1-2FT alpha 1-3FT and alpha 1-4FT were higher in endometrial cancer than those in normal endometrium. Endometrial cancer with a poor prognosis tended to react poorly to anti-endometrial cancer monoclonal antibody designated MSN-1, suggesting the possibility that the reactivity to MSN-1 is useful as a new prognostic factor for endometrial cancer. Cells of uterine endometrial cancer cell line SNG-II were classified into two groups according to their reactivity with MSN-1, whose antigen recognized is mainly Lewisb antigen. Using these classified cells of endometrial cancer cell line, it has revealed that the cells which strongly express H type antigen have more tendency to attach to endothelial cells and to cause metastasis than the cells which strongly express Lewisb antigen.
 ...
PMID:[Abnormal expression of carbohydrate chain and its mechanism in endometrial cancer]. 763 16

We have produced a monoclonal antibody (MSN-1), by using our endometrial cancer-cultured cell line (SNG-II) as an immunogen. MSN-1 belongs to the IgM immunoglobulin class and mainly recognized the Lewis carbohydrate moiety. It seldom, reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. So, we evaluated the effectiveness of its use in clinical application. We studied the relationship between the stage of cancer and reactivity to MSN-1, and that between the reactivity of moderately differentiated endometrial cancer to MSN-1 and a 5-year survival rate. Endometrial cancer with a poor prognosis tended to react poorly to MSN-1, suggesting the possibility that the reactivity to MSN-1 is useful as a new prognostic factor. A study of endometrial hyperplasia revealed that the reactivity to MSN-1 was high in the high risk group (individuals diagnosed as endometrial cancer later). This suggested that the analysis of the expression of the antigen recognized by MSN-1 is useful in selecting the high risk group out of patients with endometrial hyperplasia. Furthermore, we indicated that abnormal expression of the antigen recognized by MSN-1 associated with neoplasia of endometrial cells is useful in developing a new diagnostic method for example our endometrial cell enzyme immunoassay (EmC-EIA) and will be helpful in developing diagnostic approaches, such as missile therapy with a complex of MSN-1 and adriamycin for endometrial cancer.
 ...
PMID:[Characterization of anti human uterine endometrial cancer antibody (MSN-1) and its usefulness in clinical application]. 831 83

MSN-1 is a monoclonal antibody, which was raised by immunizing mice with a human endometrial cancer cell line, SNG-II. The MSN-1 specifically recognizes a blood group carbohydrate antigen, Leb. We investigated the subcellular and suborganellar localization of the MSN-1-reactive carbohydrate antigens in the endometrial adenocarcinomas and the normal endometria using immunofluorescence microscopy, confocal laser scanning microscopy, and immunoelectron microscopy. In normal endometrium, the apical plasma membranes of endometrial glandular cells were weekly positive. In contrast, in endometrial adenocarcinoma specimens, the apical plasma membranes, the lateral plasma membranes, intracytoplasmic vesicular structures, and the Golgi apparatus were strongly positive. We also found that there are differences in the manner of the distribution of the MSN-1 antigen within the Golgi apparatus between the normal and tumor samples; namely, in the endometrial adenocarcinoma cells the antigens are found abundantly throughout the Golgi apparatus or tend to be located not only at the trans side but also close to the cis side, while the localization of this antigen in normal counterpart is restricted to the trans-Golgi cisternae. These findings imply that aberrant glycosylation occurs in endometrial adenocarcinomas, presumably as a result of abnormal expression of some glycosyltransferases involving the expression of the Leb carbohydrate antigen in the Golgi apparatus.
 ...
PMID:Subcellular localization of blood group Leb carbohydrate antigen (MSN-1-reactive antigen) in endometrial cancer cells. 833 70

Forty patients, originally diagnosed as endometrial hyperplasia, were reviewed histopathologically and evaluated for immunohistochemical staining with antibodies directed against TAG-72 and MSN-1 antigens. All patients had follow-up endometrial biospies or hysterectomies from 1 to 13 years later. The extent of regression to normal of nonhyperplastic endometrium, persistence as any type of endometrial hyperplasia, or progression to endometrial adenocarcinoma was correlated with the histologic hyperplastic subtype and immunohistochemical staining. As expected, cases of complex or atypical hyperplasia more often progressed to carcinoma than cases of simple or no hyperplasia. Interestingly, MSN-1 positivity was more prevalent in cases of higher grades than lower grades of hyperplasia and was associated with the tendency to show persistent hyperplasia or progression to carcinoma. B72.3 positivity was uncommon in the hyperplastic endometrium and was not correlated with clinical regression or progression. Although the tendency for progression of endometrial hyperplasia to endometrial carcinoma is best judged histologically, MSN-1 may add prognostic information in subgroups of hyperplasia.
 ...
PMID:Use of monoclonal antibodies MSN-1 and B72.3 in the prediction of the natural history of endometrial hyperplasia. 834 62

We studied the abnormal expression of a glycoconjugate that appears in the process of neoplasia of endometrial cells and tried to shed light on the mechanism of their expression. Furthermore, we evaluated the effectiveness of its use in clinical application. 1. Investigation of abnormal expression of glycoconjugate We performed an immunohistochemical study on the expression of blood group-related carbohydrate antigens in endometrial cells, and found that carbohydrate side chains with galactose and fucose at their terminals were increased in association with neoplastic transformation. Using anti-endometrial cancer monoclonal antibody MSN-1, we showed that abnormal expression had already been induced in endometrial hyperplasia and increased as the lesions grew worse. A biochemical study of glycolipids showed that sulfatide (one of the sulfoglycolipids) was produced in endometrial cells, and that it varied in amount depending on the menstrual cycle, and was increased in endometrial cancer cells. Hydroxylation, which is recognized in cells in the fetal period, was seen in the ceramide region of these glycolipids. 2. Shedding light on the mechanism of the abnormal expression of glycoconjugate We examined normal and neoplastic endometrial cells for differences in the level of galactosyltransferase (GT) and fucosyltransferase (FT). Immunohistochemical staining with monoclonal antibody 8628 (an anti-GT antibody) gave the following results: GT gave a fine granular staining confined to the cytoplasma between the nucleus and glandular lumen in 70% of the cares of normal endometrium: In contrast, GT was found extensively in either a coarse granular state or spread diffusely throughout the cytoplasm in about 70% of the endometrial cancer specimens. We were also able to determine FT activity in normal and cancerous endometrial tissues by our newly developed method. The levels of alpha1-2FT, alpha 1-3FT and alpha 1-4FT were higher in endometrial cancer than in normal endometrium. Furthermore, we determined the activity of alpha 1-2FT and alpha 1-4FT in both endometrial cancer tissue and cell cultures derived from gynecological cancer, and examined the relationship between their activity levels and expression of the antigen recognized by MSN-1. There was a positive correlation between them. SNG-II cells were classified in terms of their reactivity to MSN-1 into two groups: 1) SNG-S, which was strongly reactive to MSN-1, and 2) SNG-W, which was weakly reactive to the antibody. FT activity was compared between these two cell groups. There was a marked difference in alpha 1-4FT activity between these two groups.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Abnormal expression of glycoconjugate associated with the development of endometrial cancer: a basic study and its usefulness in clinical application]. 837 Oct 8


1 2 Next >>